Compare Lam Research Corporation (LRCX) vs Oscar Health Inc (OSCR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lam Research Corporation vs Oscar Health Inc — how do they compare? Lam Research Corporation trades at $327.27 (market cap $389.67B), while Oscar Health Inc trades at $29.53 (market cap $8.63B). The key difference: Lam Research Corporation is far larger — about 45.2× Oscar Health Inc's market cap, and Lam Research Corporation pays a 0.33% dividend while Oscar Health Inc pays none. Which is the better fit depends on your goals.
| LRCX | OSCR | |
|---|---|---|
Market Cap | $389.67B | $8.63B |
Sector | Technology | Health |
52-Week High | $433.33 | $32.18 |
52-Week Low | $97.03 | $10.85 |
Enterprise Value | $387.83B | $4.99B |
Dividend Yield | 0.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lam Research (LRCX) trades at $326.02, up 6.4% in 24 hours, with a bullish technical signal and strong earnings beats. The stock shows robust fundamentals with a 29.06% net income margin and 65.07% ROE in 2025, supported by positive analyst sentiment and expansion into panel-level packaging. Recent news highlights AI-driven semiconductor demand as a key growth catalyst.
Outlook remains positive given consensus price target of $397.18 and 78% buy ratings, though high P/E of 54.06 and competitive pressures from new entrants like SpaceX's Terrafab pose risks. Revenue growth to $23.2B in 2026 suggests sustained momentum, but investors should monitor execution amid industry volatility.
Oscar Health (OSCR) trades at $29.61, up 7.01% today, with technical indicators showing a bearish trend but oversold RSI signals. The company reported strong Q2 2026 earnings, beating EPS estimates with $1.1 per share, and raised its full-year outlook amid membership growth and cost control. Revenue surged 70% year-over-year to $4.9 billion for the first half of 2026, driving a net income turnaround to $551 million for the full year 2026.
The outlook is positive with robust revenue growth and profitability improvements, though risks include competitive pressures and reliance on Obamacare policies. Analysts have a consensus price target of $32.50, suggesting moderate upside, but hold ratings dominate due to execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lam Research Corporation
Lam Research manufactures equipment used to fabricate semiconductors. The firm is focused on the etching, deposition, and clean markets, which are key steps in the semiconductor manufacturing process, especially for 3D NAND flash storage, advanced DRAM, and leading-edge logic/foundry chipmakers. Lam's flagship Kiyo, Vector, and Sabre products are sold in all major geographies to key customers such as Samsung Electronics, Micron, Intel, and Taiwan Semiconductor Manufacturing.
Read more on LRCX →About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →
